(Q36984240)

17 August 2017

1 reference

title

Idiosyncratic drug-induced liver injury: an overview (English)

1 reference

17 August 2017

S Hyder Hussaini

1

1 reference

17 August 2017

Elizabeth A Farrington

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Drug Safety

17 August 2017

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

673-684

1 reference

Drug-induced hepatic disorders. Incidence, management and avoidance

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Drug-induced hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Criteria of drug-induced liver disorders. Report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Drug-induced liver injury: summary of a single topic clinical research conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Vanishing bile duct syndrome in drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Idiosyncratic drug reactions: the reactive metabolite syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Mitochondria in steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

The natural history of histologically proved drug induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Incidence of drug-induced hepatic injuries: a French population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Accuracy of hepatic adverse drug reaction reporting in one English health region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Attitudinal survey of voluntary reporting of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Antibiotic therapy: a major cause of drug-induced jaundice in southwest England.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Incidence of drug-induced liver injury in medical inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Review article: drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Quinolones may induce hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Cholestatic hepatitis related to quinolones: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Diclofenac-associated hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Liver transplantation for acute liver failure from drug induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Apoptosis-regulating proteins as targets for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Drug-induced immunotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

HLA association of amoxicillin-clavulanate--induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Molecular pathogenesis of cholestasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Drug-induced hepatotoxicity: 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Diabetes increases the risk of acute hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.6.673

21 January 2018

Identifiers

DOI

10.1517/14740338.6.6.673

1 reference

17 August 2017

1 reference